ISSUE 3 YEAR 2 OCTOBER 2011

ACR 2011: DO NOT MISS !Basic ResearchRheumatoid ArthritisSpondyloarthritisConnective Tissue Diseases

VasculitisImagingOsteoarthritisFibromyalgiaMetabolic & Crystal ArthropathiesOsteoporosis & Metabolic Bone Disease

Dear young rheumatologists andresearchers in rheumatology,It is a great pleasure for us toshare one more issue ofEMEUNEWS with you. We madea selection of what we believe tobe the most interesting and “donot miss” presentations at ACR2011, in Chicago. Promotingeducation and research is part ofEMEUNET’s mission statementand sharing information andknowledge between youngrheumatologists and researchersis one of EMEUNET’s aims inorder to promote excellence inrheumatology.This “do not miss” newsletter ispart of EMEUNET´s activities toachieve these goals. Ournewsletters cover EULAR andACR (“do not miss“ and“highlights” newsletters) andregular newsletters are beingprepared, with more informationabout our activities, beyond thetwo main conferences. Weexpect to be able to give youvery good reasons to stayconnected to EMEUNET (moreinformation on how to sign up atthe end of the newsletter).Best wishes and have a greatCongress!Pedro Machado & Sofia Ramiro(Portugal), newsletter editors

"Do not miss" at ACR 2011 !

emeuneWSemeunetTHE EMERGING EULAR NETWORK

THE NEWSLETTER OF

Original templateHans Ulrich Scherer(The Netherlands)

EDITORIAL

BASIC RESEARCH II (Hans Ulrich Scherer)

Sofia Ramiro, MD MSc, is aRheumatology fellow at HospitalGarcia de Orta (Portugal) andcurrently a PhD candidate (researchfocus on spondyloarthritis) at theAcademic Medical Center/Universityof Amsterdam (Prof. R. Landewé andProf. D. van der Heijde). Master’s inEpidemiology at MaastrichtUniversity.

Pedro Machado, MD MSc, is arheumatology fellow at CoimbraUniversity Hospital (Portugal),currently doing research inspondyloarthritis as a doctoral fellowat the Department of Rheumatology,Leiden University Medical Center(Prof. D. van der Heijde and Prof. R.Landewé).

BASIC RESEARCH I (Caroline Ospelt & Mojca Frank)

Hans Ulrich Scherer is an MD and research fellow at theDepartment of Rheumatology at Leiden University, TheNetherlands. He is working on the etiology and pathogenicfunction of ACPA in RA and on the glycosylation ofautoantibodies.

Caroline Ospelt started her medical studies at the Leopold­Franzens University of Innsbruck, Austria in 1995 andfinished in 2003 with her doctorate thesis. Since 2003 sheworks as a post­doctoral fellow in the Center of ExperimentalRheumatology, Zurich, Switzerland.

ORAL PRESENTATIONS:Sunday, November 6, 2011, 3:45 PMSession: RA ­ Human Etiology and Pathogenesis I: Pathogenesisof the Earliest Stages of RA (W471b)Maria J. H. de Hair et al (The Netherlands)Presentation 770: Synovial Inflammation and Expression ofMediators of Pain in Preclinical RA Subjects with ArthralgiaTuesday, November 8, 2011, 4:30 PMSession: RA ­ Human Etiology and Pathogenesis II:Pathogenesis of RA ­ What's New? (W196a)Kazuhisa Nakano et al (Japan)Presentation 2517: Unique DNA Methylome Signature in RATuesday, November 8, 2011, 5:15 PMSession: RA ­ Human Etiology and Pathogenesis II:Pathogenesis of RA ­ What's New? (W196a)Emmanuel Karouzakis et al (Switzerland)Presentation 2520: Epigenome Analysis Reveals TBX­5 As aNovel Transcription Factor Involved in the Activation of RASynovial FibroblastsSunday, November 6, 2011, 5:00 PMSession: RA ­ Animal Models I (W475a)Monica Guma et al (United States)Presentation 833: Why p38 Inhibitors Are Ineffective in RA:Increased Pro­Inflammatory Macrophage FunctionPOSTERS:Monday, November 7, 2011, 9:00 AM­6:00 PMSession: Innate Immunity and Rheumatic Disease (Hall F2 ­Poster Hall)Ghada Alsaleh et al (France)Presentation 978: MiR­20a Regulates Negatively TLR4Signalling Pathway by Targeting ASK1 in RheumatoidSynoviocytesMonday, November 7, 2011, 9:00 AM­6:00 PMSession: RA ­ Animal Models (Hall F2 ­ Poster Hall)Corinna Wehmeyer et al (Germany)Presentation 1150: Deficiency of the Wnt­Inhibitor SclerostinPromotes Inflammatory Joint Destruction in the Human TumorNecrosis Factor Alpha Transgenic Mouse Model of RA

Mojca Frank, MD PhD, graduated at the Faculty of Medicine,University of Ljubljana (2005) and gained her PhD inBiomedicine, University of Ljubljana in 2010. Since 2011 sheworks as a postdoctoral research fellow in the Center forExperimental Rheumatology, Zurich, Switzerland.

ORAL PRESENTATIONS:Sunday, November 6, 2011, 5:30 PMSession: Innate Immunity and Rheumatic Disease (W474a)Michael Bonelli et al (Austria)Presentation 817: Abatacept (CTLA­4Ig) Treatment ReducesAdhesion and Migratory Capacity of Monocytes in Patients withRATuesday, November 8, 2011, 5:15 PMSession: B­cell Biology and Targets in Autoimmune Disease(W475a)Lars Rönnblom et al (Sweden)Presentation 2496: B Cells Enhance the Type I InterferonProduction by Plasmacytoid Dendritic Cells Via CD31Sunday, November 6, 2011, 5:00 PMSession: T­cell Biology and Targets in Autoimmune Disease:Lymphocyte Biology and Targets in Autoimmune Disease(W192b)Laura Su et al (USA)Presentation 851: Citrullinated Fibrinogen­Specific CD4+ T CellsDisplay Memory and Regulatory PhenotypesTuesday, November 8, 2011, 4:45 PMSession: RA ­ Human Etiology and Pathogenesis II: Pathogenesisof RA ­ What's New? (W196a)Jose U. Scher et al (USA)Presentation 2518: A Distinctive Oral Microbiome CharacterizesPeriodontitis in Patients with Early RAPOSTERS:Tuesday, November 8, 2011, 9:00 AM­6:00 PMSession: T­cell Biology and Targets in Autoimmune Disease:Lymphocyte Biology and Targets in Autoimmune Disease (Hall F2­ Poster Hall)Jan Piet van Hamburg et al (Netherlands)Presentation 2357: Th17 but Not Th22 Cells Display PathologicalBehaviour in RA Synovial InflammationSunday, November 6, 2011, 9:00 AM­6:00 PMSession: Cytokines, Mediators, and Gene Regulation (Hall F2 ­Poster Hall)Yiyun Yu et al (USA)Presentation 65: Leptin Promotes Th17 Responses

In this edition of EMEUNEWS we would like to draw your attention towhat we believe are the most interesting presentations at this year's ACR

02 OCTOBER 2011 EMEUNEWSRHEUMATOID ARTHRITIS I (Cécile Gaujoux­Viala) RHEUMATOID ARTHRITIS II (Anna Moltó)

Cécile Gaujoux­Viala, MD PhD fellow in the graduate school BioSE, occupies a half­time clinical and half­time research and teaching position at the Paris 6 Universityand Pitié­Salpêtrière Hospital in Paris. Her major research interest is outcomeassessment, in particular evaluation of the benefits in health in bone and jointdiseases, especially in rheumatoid arthritis.

Anna Moltó undertook her Rheumatology residency in Hospital Germans Trias iPujol (Barcelona). Master in clinical investigation 2009 (Universitat Autònoma deBarcelona). Intern Fellowship in Rheumatology in Lariboisière Hospital (Pr T.Bardin, Paris). She is currently an attending Rheumatologist, Rheumatology BDepartment (Pr M. Dougados), Cochin Hospital, Paris.

ORAL PRESENTATIONS:Sunday, November 6, 2011, 2:45 PMSession: RA – Human Etiology and Pathogenesis I: Pathogenesis of the EarliestStages of RA (W471b)Ted R. Mikuls et al (USA)Presentation 766: Porphyromonas Gingivalis (P. gingivalis) is Associated with thePresence of Disease­Specific Autoantibodies in Individuals At Increased Risk for theFuture Development of RAMonday, November 7, 2011, 4:30 PMSession: RA Treatment – Small Molecules, Biologics, Therapy: Existing DMARDs –Tight Control, Induction and Drug Withdrawal (W375c)Marije F. Bakker et al (Netherlands)Presentation 1695: Double­Blind Randomized CAMERA­II Trial: Better Control ofDisease and Erosive Joint Damage with Inclusion of Low­Dose Prednisone Into aMTX­Based Tight Control Strategy for Early RAMonday, November 7, 2011, 4:45 PMSession: RA Treatment – Small Molecules, Biologics, Therapy: Existing DMARDs –Tight Control, Induction and Drug Withdrawal (W375c)James R. O'Dell et al (USA)Presentation 1696: Validation of Methotrexate First Strategy in Early RA: ARandomized, Double­Blind, 2­Year TrialWednesday, November 9, 2011, 9:00 AMSession: RA Clinical Aspects: Risk of Cardiovascular Disease (W196b )Elke. E.A. Arts et al (Netherlands)Presentation 2585: Risk of Cardiovascular Disease in RA Is Independent of DiseaseDuration and the Level of Disease ActivityPOSTERS:Monday, November 7, 2011, 9:00 AM­6:00 PMSession: RA Clinical Aspects: Cardiovascular Disease in RA; Infection and RA; DrugStudies and Safety; Risk Factors for RA (Hall F2 ­ Poster Hall)Androniki Bili et al (USA)Presentation 1168: Prolonged Hydroxychloroquine Use Is Associated withDecreased Incidence of Cardiovascular Disease in RA PatientsTuesday, November 8, 2011, 9:00 AM­6:00 PMSession: RA ­ Human Etiology and Pathogenesis (Hall F2 ­ Poster Hall)Gary A. Kunkel et al (USA)Presentation 2172: Association of Particulate Air Pollution Exposure with Anti­Citrullinated Protein Antibody Elevation in RA Patients

ORAL PRESENTATIONS:Sunday, November 6, 2011, 5:15 PMSession: RA Treatment ­ Small Molecules, Biologics, Therapy: Biomarkers (W375b)Zoltan Konthur et al (Germany)Presentation 840: Protein Array Screening Reveals Autoantigenicity PatternsPredicting Anti­TNF Alpha Therapy Response in RA PatientsMonday, November 7, 2011, 2:30 PMSession: RA Treatment ­ Small Molecules, Biologics, Therapy: Existing Biologics(W375c)Jacques­Eric Gottenberg et al (France)Presentation 1641: Low Serum IgG Level After Rituximab Is Associated with AnIncreased Risk of Serious Infections in RA: Data of the AIR RegistryMonday, November 7, 2011, 3:00 PMSession: RA Treatment ­ Small Molecules, Biologics, Therapy: Existing Biologics(W375c)Edward M. Vital et al (United Kingdom)Presentation 1643: B Cell Repopulation and Rheumatoid Factor Predict Duration ofResponse to Rituximab in RATuesday, November 8, 2011, 5:00 PMSession: RA Treatment ­ Small Molecules, Biologics, Therapy: Further Insights IntoEfficacy and Safety of TNF­Inhibitors (W375a)Louise K. Mercer et al (United Kingdom)Presentation 2525: The Risk of Solid Cancer in Patients Receiving Anti­TNFTherapy for RA for up to 5 Years: Results From the British Society forRheumatology Biologics RegisterPOSTERS:Monday, November 7, 2011, 9:00 AM­6:00 PMSession: RA Treatment ­ Small Molecules, Biologics, Therapy III (Hall F2 ­ PosterHall)Edward Keystone et al (Canada and International collaboration)Presentation 2208: Sustained Inhibition of Structural Damage in Patients with RAand An Inadequate Response to TNF Inhibitors Prior to Rituximab Treatment: 5­Year Data From the REFLEX StudyMonday, November 7, 2011, 9:00 AM­6:00 PMSession: RA Treatment ­ Small Molecules, Biologics, Therapy III (Hall F2 ­ PosterHall)Sudipto Das et al (United Kingdom)Presentation 2252: Cell Biomarkers Allow Prediction of Improving Response onRepeat Cycles of rituximab

ORAL PRESENTATIONS:Sunday, November 6, 2011, 9:00 AMSession: ACR Immunology Updates for the Clinicians (W375a)Iain B. McInnes (United Kingdom)Speaker presentation: New Targets in RA: Syk, Jaks and BtkWednesday, November 9, 2011, 9:15 AMSession: RA Treatment – Small Molecules, Biologics, Therapy: Novel Compounds I(W375b)Désirée van der Heijde et al (Netherlands)Presentation 2592: Tofacitinib (CP­690,550), An Oral Janus Kinase Inhibitor, inCombination with Methotrexate Reduced the Progression of Structural Damage inPatients with RA: a 24­Month Phase 3 StudyWednesday, November 9, 2011, 12:15 PMSession: RA Treatment – Small Molecules, Biologics, Therapy: Novel Compounds II(W196b)Benjamin Hsu et al (United States)Presentation 2632: Results From a Multicenter, International, Randomized, Double­Blind, Placebo­Controlled, Phase 2 Study of Sirukumab, a Human Anti­IL­6Monoclonal Antibody, in Patients with Active RA Despite Methotrexate Therapy

Wednesday, November 9, 2011, 9:30 AMSession: RA Treatment – Small Molecules, Biologics, Therapy: Novel Compounds I(W375b)Roy M. Fleischmann et al (United States)Presentation 2593: The Oral S1P Lyase Inhibitor LX3305 (LX2931) DemonstratesFavorable Safety and Potential Clinical Benefit at 12­Weeks in a Phase 2 Proof­of­Concept Trial in Patients with Active RA on Stable Methotrexate TherapyPOSTERS:Sunday, November 6, 2011, 9:00 AM­6:00 PMSession: RA ­ Human Etiology and Pathogenesis (Hall F2 ­ Poster Hall)Kunihiro Yamaoka et al (Japan)Presentation 451: Tofacitinib Reduces Interleukin­6 and Matrix Metalloproteinase­3Production and Inhibits Cartilage Destruction in RATuesday, November 8, 2011, 9:00 AM­6:00 PMSession: RA Treatment ­ Small Molecules, Biologics, Therapy III (Hall F2 ­ PosterHall)Nicolas Wisniacki et al (United Kingdom)Presentation 2201: A Phase I, Randomized, Double­Blind, Placebo­Controlled,Single­Dose, Dose Escalation Study to Evaluate the Safety, Tolerability andPharmacokinetics of BIIB023 (Anti­TWEAK) in Subjects with RA

RHEUMATOID ARTHRITIS III (Sander Tas)

Sander W. Tas, MD PhD, is an Internist­Rheumatologist at the Academic MedicalCenter (AMC)/University of Amsterdam. His research interests are rheumatoidarthritis, NF­kappaB signaling, dendritic cells, angiogenesis and gene therapy.

EMEUNEWSAXIAL SPONDYLOARTHRITIS (Isabel Castrejón)

SYSTEMIC LUPUS ERYTHEMATOSUS & ANTIPHOSPHOLIPID SYNDROME (Neil Basu)

Laure Gossec, the current lead of EMEUNET, is associate professor of rheumatologyin Cochin Hospital, Paris, France but is currently working in the ManchesterEpidemiology Unit (UK). Her main interests are outcomes research and patient­reported outcomes, in particular in rheumatoid arthritis and psoriatic arthritis.

Isabel Castrejon, MD, is a clinical research fellow working in a research programconcerning outcomes in rheumatic diseases in the Division of Rheumatology, Hos­pital for Joint Diseases, NY, under the supervision of Professor Theodore Pincus.She was trained in Rheumatology at the Hospital Universitario de La Princesa,Madrid (2007).

Neil Basu is a consultant rheumatologist currently completing a PhD inepidemiology at the University of Aberdeen, Scotland. His main research interestslie in the field of vasculitis and the investigation of rheumatic fatigue.

ORAL PRESENTATIONS:Sunday, November 6, 2011, 3:00 PMSession: Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects andTreatment I (W470b)I Mc Innes et al (Unit Kingdom and International collaboration)Presentation 779: Anti­Interleukin 17A Monoclonal Antibody Secukinumab ReducesSigns and Symptoms of Psoriatic Arthritis in a 24­Week Multicenter, Double­Blind,Randomized, Placebo­Controlled TrialTuesday, November 8, 2011, 3:00 PMSession: Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects andTreatment (W475a)Lihi Eder et al (Canada)Presentation 2486C: Gender Related Differences in Severity of Psoriatic ArthritisTuesday, November 8, 2011, 3:45 PMSession: Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects andTreatment (W475a)Zoe R. Ash et al (United Kingdom)Presentation 2586F: Nail Disease in Psoriasis Is Associated with SonographicallyDetermined Systemic Subclinical EnthesopathyWednesday, November 9, 2011, 11:15 AMSession: Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects andTreatment IV (W196a)Asena Bahce­Altuntas et al (USA)Presentation 2634: Higher Frequency of Metabolic Syndrome in Psoriatic ArthritisCompared with RA May Be Explained by High Triglycerides and Increased Rates ofObesity and DiabetesPOSTERS:Monday, November 7, 2011, 9:00 AM­6:00 PMSession: Spondylarthropathies and Psoriatic Arthritis ­ Clinical Aspects andTreatment II (Hall F2 ­ Poster Hall)Bruce W. Kirkham et al (United Kingdom)Presentation 1288: Early Treatment of Psoriatic Arthritis Is Associated with ImprovedOutcomes: Findings From the Etanercept (Enbrel ®) PRESTA TrialMonday, November 7, 2011, 9:00 AM­6:00 PMSession: ARHP Epidemiology and Public Health (Hall F2 ­ Poster Hall)Majed M. Khraishi et al (Canada)Presentation 1548: Analysis of Radiographic Changes in Patients with EarlyPsoriatic Arthritis

ORAL PRESENTATIONS:Monday, November 7, 2011, 3:15 PMSession: Spondylarthropathies and Psoriatic Arthritis ­ Clinical Aspects andTreatment II (W181b)Pedro Machado et al (Netherlands & Portugal)Presentation 1650: Smokers in Early Axial Spondyloarthritis Have An EarlierDisease Onset, More Inflammation and Damage: Results From the DESIR CohortTuesday, November 8, 2011, 2:45 PMSession: Spondylarthropathies and Psoriatic Arthritis ­ Clinical Aspects andTreatment (W475a)Denis Poddubnyy et al (Germany)Presentation 2486B: NSAIDs Reduce Radiographic Spinal Progression in Patientswith Ankylosing Spondylitis but Not in Non­Radiographic Axial SpondyloarthritisTuesday, November 8, 2011, 3:15 PMSession: Spondylarthropathies and Psoriatic Arthritis ­ Clinical Aspects andTreatment (W475a)Xenofon Baraliakos et al (Germany)Presentation 2486D: Interleukin­17A Blockade with Secukinumab Reduces SpinalInflammation in Patients with Ankylosing Spondylitis As Early As Week 6, AsDetected by Magnetic Resonance ImagingWednesday, November 9, 2011, 12:00 PMSession: Spondylarthropathies and Psoriatic Arthritis ­ Clinical Aspects andTreatment IV (W196a)Michael J. Nissen et al (Switzerland)Presentation 2637: The Effect of DMARD Co­Therapy on Anti­TNF Drug Retentionin 1630 Spondyloarthritis PatientsPOSTERS:Sunday, November 6, 2011, 9:00 AM­6:00 PMSession: Spondylarthropathies and Psoriatic Arthritis ­ Clinical Aspects andTreatment ­ Poster I (Hall F2 ­ Poster Hall)Grace Yoon et al (USA)Presentation 512: Clinical Predictors Associated with Severe RadiographicSacroilitis in Axial SpondyloarthritisSunday, November 6, 2011, 9:00 AM­6:00 PMSession: Spondylarthropathies and Psoriatic Arthritis ­ Clinical Aspects andTreatment ­ Poster I (Hall F2 ­ Poster Hall)Karen Minde Fagerli et al (Norway)Presentation Number 533: Predictors of ASDAS Major Improvement in Patientswith Ankylosing Spondylitis Receiving Their First TNF Inhibitor. Results From aLongitudinal Observational Study

ORAL PRESENTATIONS:Sunday, November 6, 2011, 3:00 PMSession: Antiphospholipid Syndrome (W475a)Chary Lopez­Pedrera et al (Spain and International collaboration)Presentation 725: Mitochondrial Dysfunction in Monocytes From AntiphospolipidSyndrome Patients: Implications in the Pathogenesis of the Disease and Effects ofCoenzyme Q TreatmentMonday, November 7, 2011, 5:15 PMSession: SLE – Clinical Aspects: General (W183a)Yongfei Fang et al (China)Presentation 1710: The Resting State and Task Based Functional MagneticResonance Imaging Study in Non­Neuropsychiatric Systemic Lupus ErythematosusMonday, November 7, 2011, 3:30 PMSession: SLE – Human Etiology and Pathogenesis I (W183a)Melissa E. Munroe et al (USA)Presentation 1663: Altered Soluble Mediators of Inflammation At Baseline inIndividuals Who Subsequently Transition to Systemic Lupus Erythematosus: EarlyStudies From the Lupus Autoimmunity in Relatives (LAUREL) Study

Monday, November 7, 2011, 4:45 PMSession: SLE – Clinical Aspects: General (W183a)Michelle Petri et al (USA and International collaboration)Presentation 1708: Derivation and Validation of Systemic Lupus InternationalCollaborating Clinics Classification Criteria for Systemic Lupus ErythematosusPOSTERS:Sunday, November 6, 2011, 9:00 AM­6:00 PMSession: SLE – Clinical Aspects I (Hall F2 ­ Poster Hall)Benjamin Terrier et al (France)Presentation 577: Restoration of Regulatory T Cells­Th17 Cells Balance inSystemic Lupus Erythematosus Through Vitamin D SupplementationTuesday, November 8, 2011, 9:00 AM­6:00 PMSession: SLE – Clinical Aspects III (Hall F2 ­ Poster Hall)Murray B. Urowitz et al (Canada and International collaboration)Presentation 2262: Adjusted Framingham Risk Factor Scoring for Systemic LupusErythematosus

OCTOBER 2011 03PSORIATIC ARTHRITIS (Laure Gossec)

04 OCTOBER 2011 EMEUNEWSOTHER CONNECTIVE TISSUE DISEASES & VASCULITIS(Ingo Helmut Tarner & Gulen Hatemi)

OSTEOARTHRITIS & FIBROMYALGIA (Ladislav Senolt)Ladislav Senolt is a consultant rheumatologist, senior lecturer (Assoc. Prof.)and head of connective tissue research laboratory, Institute of Rheumatologyin Prague, Czech Republic.

Ingo H. Tarner, MD is a Rheumatologist and physician scientist at the University ofGiessen, Dpt. of Internal Medicine and Rheumatology, Germany, and chairman of theEUSTAR Young Investigator Group.

Gulen Hatemi, MD is a rheumatologist in Istanbul University, Cerrahpasa MedicalSchool, Department of Internal Medicine, Division of Rheumatology. Her main areasof research interest are Behçet’s syndrome, familial Mediterranean fever andvasculitis.

IMAGING (Espen A. Haavardsholm)Espen A. Haavardsholm, MD PhD, is leader for the clinical research section of theoutpatient clinic at the Dept. of Rheumatology, Diakonhjemmet Hospital, Norway.Main research interests: Imaging in inflammatory rheumatic diseases ­ especiallyMRI and US.

ORAL PRESENTATIONS:Sunday, November 6, 2011, 5:15PMSession: Systemic Sclerosis Fibrosing Syndromes and Raynaud’s – Clinical Aspectsand Therapeutics I (W192b)Adam Doré et al (USA)Presentation 846: The Significance of Tendon Friction Rubs in Early DiffuseSystemic Sclerosis PatientsSunday, November 6, 2011, 5:45PM.Session: Systemic Sclerosis Fibrosing Syndromes and Raynaud’s – Clinical Aspectsand Therapeutics I (W192b)Fabian A. Mendoza et al (USA)Presentation 848: A Prospective Observational Study of Mycophenolate MofetilTreatment in Rapidly Progressive Diffuse Cutaneous Systemic Sclerosis of RecentOnsetSunday, November 6, 2011, 2:30PMSession: Vasculitis I (W192b)David Saadoun et al (France)Presentation 791: Immunological Signature Discriminates Active and InactivePatients with Takayasu ArteritisSunday, November 6, 2011, 4:30 PMSession: Vasculitis II (W196b)Christian Pagnoux et al (France)Presentation 858: Churg–Strauss Syndrome: Description and Long­Term Follow­upof the 383 Patients Enrolled In the FVSG CohortPOSTERS:Monday, November 7, 2011, 9:00 AM­6:00 PMSession: Systemic Sclerosis, Fibrosing Syndromes and Raynaud’s ­ Pathogenesis,animal Models and Genetics I (Hall F2 ­ Poster Hall)Jérôme Avouac et al (France)Presentation 1499: Angiogenic Biomarkers Predict the Development of Digital Ulcersin Patients with Systemic SclerosisTuesday, November 8, 2011, 9:00 AM­6:00 PMSession: Vasculitis II (Hall F2 ­ Poster Hall)Gunnar Thomasson et al (USA)Presentation 2369: Optimal Definition for The Duration of Sustained Remission inANCA Associated Vasculitis

ORAL PRESENTATIONS:Sunday, November 6, 2011, 4:30 PMSession: Imaging of Rheumatic Disease I: Ultrasonography and DEXA (W181b)Stephanie Finzel et al (Germany)Presentation 807: Can Ultrasound (PDUS) Easily Detect Erosions? Evaluation ofPhysiological and Abnormal Cortical Breaks of Small Joints in Healthy Individuals(HI) and RA Patients by PDUS Comparison with Micro Computed Tomography(µCT) ScanMonday, November 7, 2011, 2:30 PMSession: Imaging of Rheumatic Disease II: X­ray, CT and MRI (W474a)Stephanie Finzel et al (Germany)Presentation 1611: Comparative Analysis of Bone Erosions and Cysts in RA,Psoriatic Arthritis and Erosive Hand OsteoarthritisMonday, November 7, 2011, 2:45 PMSession: Imaging of Rheumatic Disease II: X­ray, CT and MRI (W474a)Charles G. Peterfy et al (USA)Presentation 1612: Baseline Levels of the Inflammatory Biomarker C­ReactiveProtein Are Significantly Correlated with Magnetic Resonance Imaging Measures ofSynovitis At Baseline and After 26 Weeks of Treatment in Patients with Early RAMonday, November 7, 2011, 3:15 PMSession: Imaging of Rheumatic Disease II: X­ray, CT and MRI (W474a)Josef Smolen et al (Austria)Presentation 1614: Tocilizumab (TCZ) Inhibits Progression of Joint Damage in RAIrrespective of Its Antiinflammatory Effects: Disassociation of the Link BetweenInflammation and DestructionPOSTERS:Sunday, November 6, 2011, 9:00 AM­6:00 PMSession: Imaging of Rheumatic Disease: Ultrasound, Optical and PreclinicalImaging (Hall F2 ­ Poster Hall)Abhijit J. Chaudhari et al (USA)Presentation 1611: Molecular Imaging of Rheumatoid, Psoriatic and Osteoarthritisin the HandMonday, November 7, 2011, 9:00 AM­6:00 PMSession: Imaging of Rheumatic Disease: X­ray, MRI, CT and Positron EmissionTomography (Hall F2 ­ Poster Hall)Jackie L. Nam et al (United Kingdom)Presentation 1611: MRI Synovitis Is Prevalent in ACPA Positive Patients withMusculoskeletal Symptoms

ORAL PRESENTATIONS:Sunday, November 6, 2011, 4:30 PMSession: Osteoarthritis ­ Clinical Aspects I (W196a)Michelle S. Yau et al (United States)Presentation 825: Heritability and Linkage of Radiographic Progression of Hip andKnee Osteoarthritis: Results From the Longitudinal Component of the Genetics ofGeneralized Osteoarthritis StudySunday, November 6, 2011, 5:15 PMSession: Osteoarthritis ­ Clinical Aspects I (W196a)Yusuf Yazici et al (United States)Presentation 828: Efficacy of Tanezumab Compared with Non­Steroidal Anti­Inflammatory Drugs in Patients with Knee or Hip Osteoarthritis (NCT00809354)Monday, November 7, 2011, 2:45 PMSession: Fibromyalgia and Soft Tissue Disorders II (W190a)Shinichi Ogino et al (Japan)Presentation 1606: 5­HT2C Receptor Agonists Attenuate Muscle Pain in a Rat Modelof Fibromyalgia

Monday, November 7, 2011, 3:45 PMSession: Fibromyalgia and Soft Tissue Disorders II (W190a)Frederick Wolfe et al (United States)Presentation 1610: An 11­Year Longitudinal Study of Pharmacologic Therapy inFibromyalgiaPOSTERS:Tuesday, November 8, 2011, 9:00 AM–6:00 PMSession: Cytokines, Mediators, and Gene Regulation II (Hall F2 ­ Poster Hall)Susann Junker et al (Germany)Presentation 1825: Adipokine Expression in Osteoarthritis OsteophytesMonday, November 7, 2011, 9:00 AM–6:00 PMSession: Imaging of Rheumatic Disease II: X­ray, Magnetic Resonance Imaging,Computed Tomography, and Positron Emission Tomography (Hall F2 ­ PosterHall)Richard E. Harris et al (Germany)Presentation 971: Pregabalin Reduces Posterior Insula Combined Glutamateand Glutamine in Fibromyalgia

emeunet

THE EMERGING EULAR NETWORK

METABOLIC & CRYSTAL ARTHROPATHIES (Francisca Sivera) OSTEOPOROSIS & METABOLIC BONE DISEASE(Peter Mandl)Francisca Sivera is a rheumatologist in Hospital de Elda, Alicante (Spain) and has

a well­known interest in crystal arthritis, having published several papers, and hasrecently been involved in the development of the EULAR recommendations on thediagnosis and management of CPPD.

Peter Mandl is a Consultant Rheumatologist, currently doing research inosteoimmunology and musculoskeletal ultrasonography as a Post­Doctoral Fellowat the Division of Rheumatology, Medical University of Vienna. Peter will serve asChairperson of EMEUNET in 2012.

ORAL PRESENTATIONS:Wednesday, November 9, 2011, 9:00 AMSession: Metabolic and crystal arthropathies: anti­gout medications – dosing,adverse effects, and economic burden (W474a)Stamp L. K. et al (New Zealand)Presentation 2579: Starting dose but not maximum maintenance dose is a risk factorfor allopurinol hypersensitivity syndrome: a proposed nomogram for safe startingdosing of allopurinolWednesday, November 9, 2011, 9:15AMSession: Metabolic and crystal arthropathies: anti­gout medications – dosing,adverse effects, and economic burden (W474a)Kim S. Y. et al (USA)Presentation 2580: Severe cutaneous reactions requiring hospitalization inallopurinol initiatorsWednesday, November 9, 2011, 9:30 AMSession: Metabolic and crystal arthropathies: anti­gout medications – dosing,adverse effects, and economic burden (W474a)Wason S. et al (USA)Presentation 2581: Colchicine dosing guidelines for gout patients with varyingdegrees of renal impairment based on pharmacokinetic data.Monday, November 7, 2011, 2:30 PMSession: Metabolic and crystal arthropathies: pathogenesis of gout, a potential noveltherapy and validity of dual energy computed tomography (W183c)Bongartz T. et al (USA)Presentation 1617: Diagnosis of gout using dual­energy computed tomography: anaccuracy and diagnostic yield studyPOSTERS:Sunday, November 6, 2011, 9:00 AM–6:00 PMSession: Metabolic and crystal arthropathies: pathogenesis, epidemiology anddiagnosis (Hall F2 ­ Poster Hall)Wang H. et al (USA)Presentation 213: Gouty enthesopathy: an important pattern of uric acid depositionin difficult to diagnose goutMonday, November 7, 2011, 9:00 AM–6:00 PMSession: Metabolic and crystal arthropathies: anti­gout therapy and outcomes (HallF2 ­ Poster Hall)Schumacher H. R. et al (USA)Presentation: 1024 Rilonacept for prevention of gout flares associated with uric acid­lowering therapy: response rate across three phase 3 clinical trials

ORAL PRESENTATIONS:Sunday, November 6, 2011, 4:30 PMSession ARHP Concurrent Sessions (W183a)Susan B. Broy (USA)Speaker presentation: Iatrogenic Misadventures in Osteoporosis TreatmentMonday, November 7, 2011, 2:45PMSession: Osteoporosis and Metabolic Bone Disease: Clinical Aspects andPathogenesis (W471b)Jean­Paul David et al (Germany)Presentation 1630: The Impact of MKK6 and MKK3 on Physiological BoneArchitecture and Postmenopausal Bone LossMonday, November 7, 2011, 3:30 PMSession: Osteoporosis and Metabolic Bone Disease: Clinical Aspects andPathogenesis (W471b)Bianca A. Lang et al (Canada)Presentation 1633: Incident Vertebral Fractures (VF) 12 Months AfterGlucocorticoid (GC) Initiation in Children with Rheumatic Disorders (RD)Tuesday, November 8, 2011, 7:30 AM ­ 8:30 AMSession: ACR State­Of­The­Art Lectures (W375a)Dallas Jones et al (USA)Speaker presentation: New Insights into Bone RemodellingPOSTERS:Monday, November 7, 2011, 9:00 AM–6:00 PMSession: Osteoporosis and Metabolic Bone Disease: Clinical Aspects andPathogenesis (Hall F2 ­ Poster Hall)Alexander G. S. Oldroyd et al (United Kingdom)Presentation 1105: The Lancaster Osteoporosis Predictor—a Novel Tool to IdentifyIndividuals with OsteoporosisMonday, November 7, 2011, 9:00 AM–6:00 PMSession: Osteoporosis and Metabolic Bone Disease: Clinical Aspects andPathogenesis (Hall F2 ­ Poster Hall)Maasa Hama et al (Japan)Presentation 1115: Bach1 Regulates Osteoclastogenesis Via Heme Oxgenase­1Dependent and Independent Pathways

EMEUNEWS OCTOBER 2011 05

More information about EMEUNET can be found in www.eular.org/emeunet.cfm.You can also reach us through the following e­mail: emeunet@eular.org.Sign in for EMEUNET! Fill in the contact form available on the website,

submit it and you will be contacted soon.The selection of presentations for this newsletter is totally personal, limited and consequently very incomplete.